Letrozol Phace

Letrozole, the active ingredient in Letrozol Phace, is an aromatase inhibitor presented as an oral tablet for oral use. It is employed to lower estrogen production and is indicated for the treatment of hormone receptor‑positive breast cancer in postmenopausal women, helping to slow tumor growth.

GNH USA supplies Letrozol Phace as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches for global distribution, with reliable logistics and support for import documentation.

Letrozole is an aromatase inhibitor used primarily in the estrogen‑dependent breast cancer treatment pathway, addressing disease at various stages.

- Early‑stage hormone receptor‑positive breast cancer (adjuvant): Reduces risk of disease recurrence after surgery. - Metastatic hormone receptor‑positive breast cancer: Delays disease progression in postmenopausal patients. - Neoadjuvant therapy for locally advanced hormone receptor‑positive breast cancer: Shrinks tumor size before surgery.

Letrozole may be associated with a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects: - Hot flashes: sudden feeling of warmth and sweating. - Joint and muscle pain: arthralgia and myalgia. - Fatigue: persistent tiredness. - Nausea: mild to moderate upset stomach.

Serious or Rare Side Effects: - Osteoporosis or bone fracture: decreased bone mineral density leading to fractures. - Severe liver injury: marked elevation of transaminases or hepatitis. - Cardiovascular events: thromboembolic disorders or myocardial infarction.

When prescribing Letrozole, clinicians should consider several precautionary measures to ensure safe use.

- Assess bone health: baseline DEXA scan recommended for osteoporosis risk. - Monitor liver function: periodic liver enzyme tests advised. - Evaluate cardiovascular risk: consider history of thromboembolism. - Review concomitant medications: avoid drugs that strongly induce CYP3A4. - Pregnancy and lactation: contraindicated; ensure effective contraception in women of childbearing potential. - Store at ambient temperature: keep below 25 °C, protect from moisture and light in original container.

Letrozole can interact with other medicines, altering its effectiveness or increasing toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce letrozole plasma levels. - Anticoagulants (e.g., warfarin): increased risk of bleeding; monitor INR closely.

Moderate Interactions (Monitor Closely): - CYP2C19 inhibitors (e.g., fluconazole): may increase letrozole exposure. - Hormone replacement therapy: may counteract estrogen‑lowering effect. - Selective serotonin reuptake inhibitors (e.g., fluoxetine): potential for altered metabolism.